| Unique ID issued by UMIN | UMIN000063721 |
|---|---|
| Receipt number | R000072917 |
| Scientific Title | Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders |
| Date of disclosure of the study information | 2026/11/21 |
| Last modified on | 2026/11/21 15:38:57 |
Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders
Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders
Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders
Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders
| Japan |
Dementia, mild cognitive impairment (MCI), and mental disorders (primarily depressive disorders, bipolar disorder, schizophrenia spectrum disorders, and delusional disorder)
| Psychiatry |
Others
NO
To explore the feasibility, tolerability, safety, acceptability, conversational characteristics, and potential psychosocial effects of a generative AI-enabled conversational robot used by adults with dementia, MCI, or mental disorders in supervised outpatient/ward settings or at home. The study also aims to identify conditions for safe implementation and future research.
Others
feasibility, acceptability, and safety
Exploratory
Pragmatic
Not applicable
(1) Completion rate of the two-week home-use period: proportion of participants who complete the installation period without discontinuation and achieve 'successful use' (at least 20 minutes of conversation per day on at least three days per week; feasibility target: 80% or higher). Days when use is impossible due to travel, hospitalization, or other unavoidable reasons are excluded; time after dropout is treated as evaluable. (2) Occurrence of serious adverse events during study participation. (3) Completion rate of the planned approximately 10-minute conversational sessions in outpatient or ward settings.
(1) User experience, psychological responses, perceived burden, and barriers to implementation/continued use assessed through semi-structured interviews with participants, family/supporters, and healthcare staff. (2) Conversational continuity, interruption/refusal, days and duration of use, number of conversations, and duration per conversation. (3) Perceptions, acceptability, attachment, usability burden, and willingness to continue use assessed using questionnaires (CCR, B-LAPS-Ro, SUS).
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
| Device,equipment |
Participants use Sota, a tabletop conversational robot powered by generative AI. In outpatient/ward settings, a researcher or healthcare staff member supervises an approximately 10-minute session; a session may be extended to 20 minutes and repeated up to three times if requested and considered safe. Supportive conversation may include reminiscence and reflection on mood or daily activities. For home use, the robot is installed for approximately two weeks for unrestricted conversational use. Researchers conduct safety checks by telephone around day 2 and week 1. When independent reporting or discontinuation is difficult, family members or visiting nurses check the participant at least three times weekly.
| 18 | years-old | <= |
| Not applicable |
Male and Female
(1) Adults aged 18 years or older with dementia, MCI, or a mental disorder (primarily depressive disorders, bipolar disorder, schizophrenia spectrum disorders, or delusional disorder). (2) Written informed consent from the participant; if consent capacity is insufficient, written consent from a legally authorized representative after confirming the participant's wishes. (3) Eligibility is assessed considering psychiatric stability, conversational ability, and study-related risk.
(1) MMSE score below 10. (2) Severe disturbance of consciousness, delirium, marked agitation/refusal, risk of self-harm or harm to others, or clear suicidal ideation. (3) Acute physical illness or psychiatric symptoms making participation medically inappropriate. (4) Inability to converse in Japanese. (5) Severe hearing or speech impairment that prevents voice interaction. (6) High risk of worsened anxiety, confusion, delusional interpretation, dependency, or other psychiatric symptoms, as determined by investigators.
50
| 1st name | Yuto |
| Middle name | |
| Last name | Satake |
Osaka University Graduate School of Medicine
Department of Psychiatry
5650871
D3, 2-2 Yamadaoka, Suita, Osaka, Japan
0668793051
y.satake@psy.med.osaka-u.ac.jp
| 1st name | Yuto |
| Middle name | |
| Last name | Satake |
Osaka University Graduate School of Medicine
Department of Psychiatry
565-0871
D3, 2-2 Yamadaoka, Suita, Osaka, Japan
08057013682
y.satake@psy.med.osaka-u.ac.jp
The University of Osaka
The University of Osaka
Profit organization
Japan
Ethical Review Board Osaka University Hospital
2-2 Yamadaoka, Suita, Osaka
06-6210-8296
rin-sokatu@dmi.med.osaka-u.ac.jp
NO
| 2026 | Year | 11 | Month | 21 | Day |
Unpublished
Preinitiation
| 2026 | Year | 11 | Month | 21 | Day |
| 2026 | Year | 12 | Month | 01 | Day |
| 2027 | Year | 12 | Month | 31 | Day |
| 2026 | Year | 11 | Month | 21 | Day |
| 2026 | Year | 11 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072917